SFT-605

SFT-605 is an investigational inhaled drug candidate being developed by invoX Pharma for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The therapy is delivered using the proprietary Softhaler® platform, a high-performance dry powder inhaler (DPI) designed to optimize drug deposition in the deep lungs while requiring minimal inspiratory effort from the patient. This localized delivery approach aims to enhance therapeutic efficacy in the pulmonary tissue while reducing the systemic side effects often associated with oral anti-fibrotic treatments. As of current pipeline reports, SFT-605 is in the preclinical stage of development. While the specific active pharmaceutical ingredient and molecular target have not been publicly disclosed, the program is a key part of invoX's strategy to apply its Softhaler technology to chronic and fibrotic respiratory diseases.